Brief: Nanobiotix Announces First Patient Injected In New Phase 1/2 Study Evaluating Radiotherapy-Activated Nbtxr3 Plus Anti-Pd-1 For Patients With Advanced Cancers
19/07/2023 21:37
July 19 (Reuters) - Nanobiotix SA NANOB.PA :
* NANOBIOTIX ANNOUNCES FIRST PATIENT INJECTED IN NEW PHASE
1/2
STUDY EVALUATING RADIOTHERAPY-ACTIVATED NBTXR3 PLUS ANTI-PD-1
FOR PATIENTS WITH ADVANCED CANCERS
Source text for Eikon: ID:nGNXQbHkK
Further company coverage: NANOB.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nanobiotix SA
See all newsBrief: Nanobiotix S.A. H1 Net Income EUR -34.3 Million
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering